Cargando…

Scripted spot removal in PBS proton therapy planning

BACKGROUND: It is well known in proton therapy that the relative biological effectiveness (RBE) is not constant across the entire Bragg peak, with higher RBE at the distal end of the Bragg peak due to higher linear energy transfer (LET). Treatment planning systems are moving toward LET optimization...

Descripción completa

Detalles Bibliográficos
Autores principales: Hedrick, Samantha G., Walker, Bryant, Morris, Bart, Petro, Scott, Blakey, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833280/
https://www.ncbi.nlm.nih.gov/pubmed/34890101
http://dx.doi.org/10.1002/acm2.13491
Descripción
Sumario:BACKGROUND: It is well known in proton therapy that the relative biological effectiveness (RBE) is not constant across the entire Bragg peak, with higher RBE at the distal end of the Bragg peak due to higher linear energy transfer (LET). Treatment planning systems are moving toward LET optimization to mitigate this potentially higher biological impact at a track end. However, using a simple script, proton users can begin to simulate this process by deleting spots from critical structures during optimization. In most cases, nominal target coverage and plan robustness remain satisfactory. METHODS: In our clinic, we developed a script that allows the user to delete spots in all organs at risk (OARs) of interest for one or more treatment beams. The purpose of this script is to potentially reduce side effects by eliminating Bragg peaks within OARs. The script was first used for prostate patients where spots in the rectum and sigmoid, outside of the overlap with the target, were deleted. We then began to use the script for head and neck (H&N) and breast/chestwall patients to reduce acute side effects of the skin by removing spots in a 0.5‐cm skin rind. CONCLUSIONS: By utilizing a simple script for deleting spots in critical structures, we have seen excellent clinical results thus far. We have noted reduced skin reactions for nearly all H&N and breast patients.